

LIFE HEALTHCARE GROUP HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 2003/002733/06)
ISIN: ZAE000145892
Share Code: LHC
("Life Healthcare" or "the Group" or "the Company")



LIFE HEALTHCARE FUNDING LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2016/273566/06)
LEI: 3789SJPQJZF8ZYXTZ394
Bond company code: LHF1

TRADING STATEMENT FOR THE SIX MONTHS ENDING 31 MARCH 2024

In terms of paragraph 3.4 (b) of the JSE Limited ("JSE") Listings Requirements, a listed company is required to publish a trading statement as soon as it is satisfied that a reasonable degree of certainty exists that the financial results for the period to be reported upon will differ by at least 20% from those of the previous corresponding period.

The Group completed the Alliance Medical Group ("AMG") disposal on 31 January 2024 as announced on the Stock Exchange News Service of the JSE ("SENS") on 2 February 2024. Details of the AMG disposal and the *pro forma* financial effects on the Group were included in the circular to Life Healthcare shareholders distributed on 9 November 2023 and updated *pro forma* financial information was released on SENS on 29 November 2023 after the publication of the Group's financial year results for the twelve months to 30 September 2023.

As a result of the AMG disposal, the Group will realise a once-off net gain of c.R2.7 billion. This once-off gain, in isolation, equates to c.187 cents per share. This gain will only impact the earnings per share ("EPS") and not the headline earnings per share or normalised earnings per share for the six months ending 31 March 2024 (the current period or H1-2024). Therefore the EPS for the current period is expected to show an increase of greater than 20% compared to the EPS of 37.9 cents reported for the six months ended 31 March 2023 (H1-2023).

The current period has not yet been concluded and the Group is therefore not in a position to provide, with certainty, an indicative earnings range for the current period. However, in order to provide shareholders and noteholders with an **indication of the isolated impact of this once-off item** on the Group's results, if the 187 cents per share is added to the EPS of 37.9 cents from H1-2023, the resulting 224.9 cents per share would represent growth of 495% year-on-year.

A further trading statement will be issued after the end of the current period, when the Group will provide shareholders and noteholders with more certainty regarding the total trading impact of H1-2024 results.

This trading statement is the responsibility of the directors and is based on financial information which represents the Group's latest financial estimates and has not been reviewed, or reported on, by Life Healthcare's external auditors.

For further information, please contact:
Mark Wadley, Head of Investor Relations
investor.relations@lifehealthcare.co.za

Dunkeld
19 February 2024

Equity and Debt Sponsor
RAND MERCHANT BANK (a division of FirstRand Bank Limited)